Rankings
▼
Calendar
AMLX Q4 2025 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMLX
Amylyx Pharmaceuticals, Inc.
$1B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
+100.0% YoY
Gross Profit
$20M
Operating Income
-$37M
Net Income
-$33M
EPS (Diluted)
$-0.28
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$28M
Free Cash Flow
-$28M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$333M
Total Liabilities
$27M
Stockholders' Equity
$305M
Cash & Equivalents
$227M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
-$665,000
+100.0%
Gross Profit
$20M
-$665,000
+3106.9%
Operating Income
-$37M
-$41M
+10.0%
Net Income
-$33M
-$38M
+12.1%
← FY 2025
All Quarters